Clinical Trial Update: Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors [Phase 1]

View source ↗

Summary

This Phase 1 trial update assesses the safety and feasibility of radiolabeled octreotide in pediatric patients with advanced or refractory solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumors
• Childhood Solid Tumors
• Gastrointestinal Carcinoid Tumor
• Islet Cell Tumor
• Neuroblastoma
• Pheochromocytoma
• Sarcoma

Drugs mentioned

• Radiolabeled octreotide (octreotide radiolabeled with radionuclide)

Snippet

Sponsor: O'Dorisio, M S | Conditions: Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor | Phase 1 | Status: COMPLETED